Mini Review

Continuous subcutaneous insulin infusion: practical issues

Banshi D. Saboo, Praful A. Talaviya
Dia Care, Diabetes care and Hormone Clinic, Ahmedabad, Gujarat, India

ABSTRACT

The growing number of individuals with diabetes mellitus has prompted new ways of treating these patients, continuous subcutaneous insulin infusion (CSII) or insulin pump therapy is an increasingly common form of intensive insulin therapy. An increasing number of individuals with diabetes mellitus individuals of all ages have started using insulin pump therapy. Not everyone is a good candidate for insulin pump therapy, and the clinician needs to be able to determine which patients are able to master the techniques required and to watch for the adverse reactions that may develop. Insulin pump increases quality of life of patient with diabetes mellitus with increasing satisfaction with treatment and decrease impact of diabetes mellitus. Manual errors by insulin pump users may lead to hypo or hyperglycemia, resulting into diabetic ketoacidosis (DKA) sometimes. Some of practical aspect is associated with insulin pump therapy such as selection of candidates, handling of pump and selection of site, and pump setting, henceforth this review is prepared to explore and solve the practical problems or issues associated with pump therapy.

Key words: CSII, diabetes mellitus, insulin pump

INTRODUCTION

Technological advances in medicine are highly anticipated and valued. As these advances gain recognition, they frequently change perspectives about appropriate treatments and may affect the information that physicians provide to families when discussing treatment options. However, it is imperative that newer treatments are evaluated to accurately identify treatment efficacy as well as possible psychosocial effects of treatment.

Continuous subcutaneous insulin infusion (CSII) was first introduced as a management strategy for both adult[1] and pediatric[2] patients with type 1 diabetes mellitus (T1DM) in the late 1970s. However, it was not until the Diabetes Control and Complications Trial[3,4] and epidemiology of Diabetes Interventions and Complications[5] studies confirmed and re-affirmed the pre-eminent role of glycemic control in the pathogenesis of microvascular complications that use of insulin pump therapy as “intensive therapy” in young people with diabetes has become increasingly widespread.

Continuous subcutaneous insulin infusion (CSII) with a portable pump is an insulin therapy system first built in 1976 by Pickup and Keen for research purposes.[1,6] At that time, the size of the pump was equal to that of a back pack. Nowadays, the size of an insulin pump is no bigger than a cell phone or a credit card. More than three lakhs patients around the world use a continuous subcutaneous insulin infusion (CSII) system today, and the number of “pumpers” is expected to increase dramatically in the next decade.[7] The potential benefits of CSII became clear after the Diabetes Control and Complications Trial (DCCT) Research Group published a report in 1993.[8] Although the basic principles remain the same, several technological improvements have occurred in the previous 15 years, making insulin pumps safer, easier, and more flexible. Although CSII or pumps are the best method of insulin delivery for patients with type 1 diabetic and type 2 diabetic...
on MDI who are motivated, technologically savvy, and have the means to pay for the technology.\[9\]

**Operating Insulin Pump**

When pump is on, it will show various icons. First, it will show a countdown, after which the screen goes dark, and then the version of the particular pump will appear on the screen. Then, a dark circle, a battery sign, and a syringe sign will appear on the screen. Generally, the battery work up to 10-12 days, and if there is a low battery alarm, then the battery should be immediately changed; some patient are commonly doing mistake in operating insulin pump by proper way; therefore, before starting pump therapy, patient or parents has to understand the basic operating function of pump.\[10\]

**Proper Selection of Site and Rotation**

Patients need to change the infusion set site every 2-3 days and should always rotate to a new site. Some pump users may need to change the site more often if they notice their blood glucose is less stable over time. The abdominal area is the most common site for set insertions. The abdomen allows for more rapid and consistent insulin absorption than from other sites, especially after exercise. When using the abdomen, help the pumper to identify a variety of abdominal sites for adequate rotation. Imagining a clock drawn on the abdomen cane helpful. Ask the patient to rotate the site in clockwise position from 12 o’clock to 3 o’clock and so on, and make sure the site is convenient to insert the cannula.

Some pumpers use the thigh or hip area; it is also possible to use areas higher on the abdomen that may have previously been used with injected insulin. Many prefer the hip area because it is “out of sight.” If these sites are used, make sure that cannula placement is subcutaneous, not intramuscular.

Make sure that your patients understand that the insulin pump will alarm only if insulin delivery is interrupted. Reinforce that the pump cannot detect and will not alarm for certain problems at the infusion site. Explain that occasionally an infusion site may temporarily cease to absorb insulin properly, resulting in hyperglycemia.

**Consideration of Candidate for Insulin Pump Therapy**

Patients should be considered for insulin pump therapy when intermittent insulin injections are not meeting treatment goals and outcome measures are sub-optimal, including, but not limited to:\[11\]

- A1C > 7.0-7.5%, accompanied by frequent severe hypoglycemia (<70 mg/dL)
- Hypoglycemic events requiring third party assistance or interfering with work, school, or family obligations
- Frequent and unpredictable fluctuations in blood glucose levels
- Patient perception that diabetes management impedes the pursuit of personal or professional goals

Prospective pump users or their care givers must be able to change infusion sets, fill pump cartridges and program the pump, and must demonstrate willingness to collaborate with healthcare providers in achieving the goals of diabetes therapy.\[11,13\] In general, patients likely to succeed on insulin pump therapy will have had sufficient education and support while using other forms of insulin therapy so that they are already competent in assessing the nutritional value of meals and monitoring blood glucose levels frequently (minimum four times a day, preferably 6-8 times) and checking ketone levels when appropriate.\[13\]

**Problem Associated with Insulin Pump Therapy**

**Discomfort**

Although the insertion devices make insertion virtually painless, a small percentage of pumpers will experience discomfort when first inserting the infusion set.

**Skin problem**

Clean technique, good hygiene, and changing the site as recommended are the best protection against skin infections. Careful attention to site preparation and daily checks of the site will prevent most infections. However, serious consequences can occur if insertion site irritation and infections are ignored. Suggestions for avoiding skin infections at insertion sites are:
Hyperglycemia
Some of pump users may suffer from hyperglycemia due to following reason:
- Due to pump catheter dislodged, blocked (partially or completely), or bent
- Due to incorrect basal rates programmed and delayed or dose not given bolus
- Sometime, pump is responsible due to pump malfunction such as dead battery/no power
- Reservoir/Cartridge (Pump Syringe): Leakage at infusion set and pump syringe, empty pump syringe
- Infusion Set: Set not primed, kinked tubing, blood in set, set in too long, set inserted at bedtime, air in set.
- Infusion Site: Irritated, red, inflamed tender, friction at site placement causing discomfort areas of hypertrophy
- Insulin: Cloudy, exposed to extreme temperatures (cold or heat)

Diabetic ketoacidosis (DKA)
DKA is a serious medical condition that results from untreated hyperglycemia. DKA needs immediate treatment. Since insulin pump therapy uses only fast-acting insulin, DKA can occur rapidly because there is no longer-acting insulin in the body as back-up.

Illness
Illness and infection put extra stress on the body, often causing a rise in blood glucose. It left untreated, hyperglycemia from illness can quickly lead to DKA. Hyperglycemia during illness is easily prevented by increasing oral fluid intake, adjustments to insulin pump doses, and more frequent blood glucose monitoring. Illness is manageable with diabetes if treatment guidelines are understood and necessary supplies are available. It is important to teach your patient to prepare for sick-days by having necessary supplies available at all times, especially when travelling.

Mechanical problems
Mechanical problems and interruptions in insulin delivery often cause unexplained highs and can progress to ketoacidosis, if they are not promptly addressed. Possible causes for unexplained highs include infusion-site problems, displaced or clogged infusion set, inactivated insulin because of degradation, or pump malfunction. Troubleshooting should include an investigation of the pump, battery, reservoir, and infusion site to determine the potential causes for unexplained highs or lows.

Tunneling (insulin return on skin surface) is common when the subcutaneous tissue becomes inflamed and swollen around the infusion site. Blockage of the infusion pipe is also a common problem. Prolonged exposure to heat can cause insulin to coagulate within the infusion set, thereby
blocking delivery. Using unbuffered regular insulin increases the risk of infusion-line clogs.[17] Insulin leakage from the tubing or reservoir can also cause unexplainable high blood glucose levels. Although insulin leakage can be difficult to detect, patients can use observation and the distinct smell of insulin to locate the leak.[18] If a clog, leak, or infusion-related issue is suspected, the entire infusion set should be replaced or should be corrected. When the blood glucose rise up to 300 mg/dL or if two consecutive readings are more than 250 mg/dL, the patient should be instructed for ketones test.[16] In addition, a correction bolus dose of insulin should be administered. The blood glucose should be monitored every 2 hours, and, if ketones are present, the patient should rehydrate with an appropriate fluid until ketones have cleared and the blood glucose has stabilized.[19] Other reasons for unexplained hyperglycemia or DKA include mechanical problems, illness or infection, incorrect bolus dosing, and degraded insulin. When faced with mechanical problems, the patient may need to remove the insulin pump and correct the error.

**Conclusion**

Insulin pump, also known as *In-vitro* pancreas and latest technological therapy, considered as standard care for type 1 diabetes mellitus and type 2 patients who developed severe beta cell failure or patients on multiple daily injections who need flexible quality of life. Some of practical issues are associated with pump therapy such as selection of candidates, site selection and rotation, setting of various pump parameters, and handling of pump in daily life. According to this review, it may conclude that for better outcome of insulin pump therapy, effective patient education is required to solve practical issues. Patient education for pump therapy should be delivered by diabetologist, diabetes educator, and pump technician.

**References**

1. Pickup JC, Keen H, Parsons JA, Alberti KG. Continuous subcutaneous insulin infusion: An approach to achieving normoglycaemia. Br Med J 1978;1:204-7.
2. Tamborlane WV, Sherwin RS, Genel M, Felig P. Reduction to normal of plasma glucose in juvenile diabetes by subcutaneous administration of insulin with a portable infusion pump. N Engl J Med 1979;300:573-8.
3. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329:977-86.
4. Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus. Diabetes Control and Complications Trial. J Pediatr 1994;125:177-88.
5. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 2000;342:381-9.
6. Pickup J, Keen H. Continuous Subcutaneous Insulin Infusion at 25 Years, Evidence base for the expanding use of insulin pump therapy in type 1 diabetes. Diab Care 2002;25:593-8.
7. Walsh J, Roberts R. Pumping insulin. 4th ed. San Diego, CA: Torrey Pines Press; 2006.
8. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329:977-86.
9. Skjølner JS, Ponder S, Kruger DF, Matheson D, Parkin CG. Is there a place for insulin pump therapy in your practice?. Clin Diabetes 2007;25:50-66.
10. Jain S. How to most out of your pump including carbohydrates counting. Bhopal, India: Manjul Publication House Pvt. Ltd.; 2008.
11. Insulin Pump Therapy: Guidelines for Successful Outcomes American Association of Diabetes Educators 2008 Consensus Summit. Chicago, Illinois. September 18, 2008.
12. American Diabetes Association. Insulin Pumps. Available from: http://www.diabetes.org/type-1-diabetes/insulinpumps.jsp. Last accessed on 2008 Oct 09.
13. American Association of Diabetes Educators. Education for continuous subcutaneous insulin infusion pumps users. Diabetes Educ 2003;29:97-9.
14. Petrovski G, Dimitrovski C, Milenkovic T. Insulin pump therapy with continuous glucose monitoring improves metabolic control in brittle type 1 diabetes. Prilozi 2007;28:129-35.
15. Litton J, Rice A, Friedman N, Oden J, Lee MM, Freemark M. Insulin pump therapy in toddlers and preschool children with type 1 diabetes. J Pediatr 2002;141:490-5.
16. Walsh J, Roberts R. Pumping insulin. 4th ed. San Diego, CA: Torrey Pines Press; 2006.
17. Medlenburg RS, Benson EA, Benson JW Jr, Fredlund PN, Guinn T, Metz RJ, et al. Acute complications associated with insulin infusion pump therapy: report of experience with 161 patients. JAMA 1984;252:3265-9.
18. Strowig SM. Initiation and management of insulin pump therapy. Diabetes Educ 1993;19:50-9.